| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (AbbVie) M16-191 | A Randomized, Open-Label, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib Alone In Subjects With Myelofibrosis | Leber, Dr Brian | Open to recruitment | NCT04472598 |
| (AbbVie) M19-708 / VIALE-M | Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) | Leber, Dr Brian | Open to recruitment | NCT04102020 |
| (AbbVie) M20-178 / TRANSFORM-2 | A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | Leber, Dr Brian | Open to recruitment | NCT04468984 |
| (Celgene) ACE-536-MDS-002 / COMMANDS | A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions | Leber, Dr Brian | Open to recruitment | NCT03682536 |
| (Constellation) CPI-0610-02 / MANIFEST study | A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) | Leber, Dr Brian | Open to recruitment | NCT02158858 |
| (Horizon Health Network) The M4 Study | The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Cohort Study (The M4 Study) | Mian, Dr Hira | Open to recruitment | NCT03421132 |
| (Janssen) 68284528MMY3004/CARTITUDE 5 | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | Aljama, Dr Mohammed | Open to recruitment | NCT04923893 |
| (McMaster) CTTC 1901 / OZM-099 | A Randomized Pilot Trial comparing Anti-Thymocyte Globulin (ATG) with ATG plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT) | Walker, Dr Irwin | Open to recruitment | NCT04202835 |
| (Novartis) CABL001J12301 | A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | Leber, Dr Brian | Open to recruitment | NCT04971226 |
| (SHSC) 3242 / BRAWM | A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom’s Macroglobulinemia | Aljama, Dr Mohammed | Open to recruitment | NCT04624906 |
| CMRG 007 / MCRN 007 / ALGONQUIN | A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM) | Mian, Dr Hira | Open to recruitment | NCT03715478 |
| CMRG 008 | A Phase 2 Multi-Center, Open Label Study of Isatuximab added to standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma | Mian, Dr Hira | Open to recruitment | NCT04786028 |
| (CCTG) LY.17 | A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Fraser, Dr Graeme | Suspended/On hold | NCT02436707 |
| (Celgene) CC-97540-NHL-001 | A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC-97540, CD19-TARGETED NEX-T CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL NONHODGKIN LYMPHOMA | Foley, Dr Ronan | Suspended/On hold | NCT04231747 |
| (Kronos Bio) KB-ENTO-3001 / AGILITY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia | Leber, Dr Brian | Suspended/On hold | NCT05020665 |
| (Karyopharm) KCP-8602-801 | A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Cancer Indications | Khalaf, Dr Dina | Suspended/On hold | NCT02649790 |
Find a Trial
Contact Us